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ABSTRACT
Introduction: Lower gastrointestinal (GI) can-
cers are a major cause of cancer deaths world-
wide. Prognosis improves with earlier diagnosis,
and non-invasive biomarkers have the potential
to aid with early detection. Substantial invest-
ment has been made into the development of
biomarkers; however, studies are often carried
out in specialist settings and few have been
evaluated for low-prevalence populations.
Methods: We aimed to identify novel
biomarkers for the detection of lower GI cancers
that have the potential to be evaluated for use
in primary care. MEDLINE, Embase, Emcare and
Web of Science were systematically searched for
studies published in English from January 2000
to October 2019. Reference lists of included
studies were also assessed. Studies had to report
on measures of diagnostic performance for
biomarkers (single or in panels) used to detect
colorectal or anal cancers. We included all
designs and excluded studies with fewer than 50
cases/controls. Data were extracted from pub-
lished studies on types of biomarkers, popula-
tions and outcomes. Narrative synthesis was
used, and measures of specificity and sensitivity
were meta-analysed where possible.
Results: We identified 142 studies reporting on
biomarkers for lower GI cancers, for 24,844
cases and 45,374 controls. A total of 378 unique
biomarkers were identified. Heterogeneity of
study design, population type and sample
source precluded meta-analysis for all markers
except methylated septin 9 (mSEPT9) and
pyruvate kinase type tumour M2 (TuM2-PK).
The estimated sensitivity and specificity of
mSEPT9 was 80.6% (95% CI 76.6–84.0%) and
88.0% (95% CI 79.1–93.4%) respectively; TuM2-
PK had an estimated sensitivity of 81.6% (95%
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CI 75.2–86.6%) and specificity of 80.1% (95%
CI 76.7–83.0%).
Conclusion: Two novel biomarkers (mSEPT9
and TuM2-PK) were identified from the litera-
ture with potential for use in lower-prevalence
populations. Further research is needed to vali-
date these biomarkers in primary care for
screening and assessment of symptomatic
patients.
Keywords: Biomarkers; Clinical practice;
Colorectal cancer; Early detection; Lower
gastrointestinal cancers; Primary care
Key Summary Points
To our knowledge, this is the first
systematic review to characterise the
range of novel biomarkers being
investigated for the early detection of
lower GI cancers, with a focus on their
readiness to progress to further evaluation
in low-prevalence populations such as
primary care.
We identified 378 unique biomarkers from
the literature; a meta-analysis of
diagnostic accuracy data indicated
mSEPT9 and TuM2-PK have potential for
further evaluation in low-prevalence
populations.
We highlight the need for (1) further
studies on mSEPT9 and TuM2-PK in low-
prevalence populations; (2) better
reporting to facilitate translation; (3) more
consistency in the use of biomarkers. By
doing so, we will be able to progress to a
different step in the evaluation process of
promising biomarkers, and ultimately
ascertain clinical benefits for our intended
population. This will require going
beyond test performance, investigating
implementation (including feasibility and
acceptability), safety and cost-
effectiveness.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13664042.
INTRODUCTION
Gastrointestinal (GI) cancers account for over
25% of global cancer incidence and 35% of all
cancer-related deaths [1]. Lower GI cancers,
particularly colorectal cancer (CRC), contribute
the most significant proportion with over 1.8
million new cases in 2018 [1]. CRC is the most
commonly diagnosed GI cancer and constitutes
1 in 10 cancer cases and deaths [1].
Around 90% of patients with cancer first
present with symptoms in primary care, high-
lighting a key role for primary care providers in
the early detection of GI cancers [2, 3]. Diag-
nosis of GI cancers can prove challenging in the
community setting: while gastrointestinal
symptoms are commonly encountered, they are
usually due to benign or self-limiting condi-
tions and rarely to GI cancer [3]. Initial symp-
toms are often non-specific, and more specific
symptoms usually represent more advanced
disease [3].
Increased demand for diagnostic services for
lower GI cancer and pressure on waiting times
have been seen internationally in countries like
Australia, the UK and Canada, where primary
care plays a ‘gatekeeping’ role to specialist care.
In many countries implementation of faecal
occult blood tests (FOBTs) or faecal immuno-
chemical tests (FITs) for CRC screening and
diagnostic triage adds further pressure on colo-
noscopy services. In some healthcare systems,
over-screening via colonoscopy is also an issue
[4]. New diagnostic approaches are needed to
help reduce the burden on specialist care, par-
ticularly in the current context of COVID-19
and associated delays in access to cancer diag-
nostic and treatment services [5].
There is considerable interest in the potential
of biomarkers to detect GI cancers [3]. To date,
carcinoembryonic antigen (CEA) and
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carbohydrate antigen 19-9 (CA19-9) have
played an important role in clinical practice to
detect recurrent disease, but their diagnostic
performance is inadequate for the early detec-
tion of new disease [3, 6, 7]. Substantial invest-
ment has been made developing new
biomarkers for early detection, but most studies
of these tests have occurred in specialist clinical
settings [8] where cancer prevalence is higher
than in the community settings where they
would eventually be applied [9, 10]
The performance characteristics of a diag-
nostic test are strongly determined by the
prevalence and severity of the target disease and
of other diseases within the study population
[9]. In populations where the prevalence of the
target disease is low (e.g. GI cancer in primary
care), the corresponding positive predictive
values (PPV) are lower than in high-prevalence
populations. Tests that are evaluated only in
these high-prevalence populations tend to have
lower sensitivity and higher specificity when
translated to low-prevalence populations
[10, 11]. This is known as the ‘spectrum effect’,
and has crucial implications for comparing the
performance of tests in different populations
[9, 10].
In recognition of these issues, the CanTest
Framework was developed (Fig. 1) [10]. This
novel framework encompasses a translational
pathway for diagnostic tests, from new test
discovery to health system implementation in
low-prevalence populations [11]. The frame-
work highlights the importance of evaluating
clinical performance, implementation, patient
safety, quality of care, and cost-effectiveness in
the intended setting. It is vital that these ele-
ments are investigated alongside test perfor-
mance in order to ascertain clinical utility and
improved outcomes for patients [8].
Fig. 1 The CanTest framework. Source: Walter et al. 2019 [10]
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This review aimed to systematically identify
novel biomarkers for the early detection of
lower GI cancers that have measures of diag-
nostic performance and show sufficient promise
to warrant further evaluation in low-prevalence
populations.
METHODS
Search Strategy and Inclusion/Exclusion
Criteria
These have been reported elsewhere [12]. The
protocol for this review was registered on
PROSPERO (registration ID CRD42020165005)
and the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis of Diagnostic
Test Accuracy Studies (PRISMA-DTA) statement
was followed [13]. MEDLINE, Embase, Emcare
and Web of Science were electronically searched
for primary studies published in English
between the 1 January 2000 and 31 October
2019. The search strategy was developed with
the assistance of a medical librarian (Ap-
pendix 1 in the supplementary material).
Studies eligible for inclusion were situated
within phase 2 (i.e. providing measures of
diagnostic accuracy beyond discovery, even if
carried out in high-prevalence settings) and
phase 3 (i.e. examining diagnostic accuracy in
intended low-prevalence settings, and provid-
ing measures of clinical utility, including feasi-
bility and acceptability) of the CanTest
framework [10] (Fig. 1). We included studies
which reported measures of diagnostic perfor-
mance in an independent population (i.e.
beyond measures from the initial discovery
phase). Studies were excluded if no references to
previous research evaluating biomarker perfor-
mance were available, and if the study provided
only one set of performance measures (reflect-
ing discovery phase only). As studies beyond
the discovery phase require larger sample sizes
[14, 15], we included those which reported data
on at least 50 cancer cases and at least one
group of homogeneous non-cancer controls (n
C 50) with similar clinical characteristics (e.g.
healthy, or with non-malignant conditions), as
in previous reviews [15, 16].
We included studies on non-invasive
biomarkers feasible for use in the community
setting: blood (serum and plasma), urine, faecal,
salivary or breath samples. Both observational
(cohort or case–control, cross-sectional or lon-
gitudinal, prospective or retrospective) and
experimental designs were eligible for inclusion.
Studies undertaken in all recruitment settings
were included.
We included studies if they reported on at
least one measure of diagnostic performance,
namely sensitivity, specificity, PPV, negative
predictive value (NPV), false positive, false
negative or area under the curve (AUC) for
biomarkers used to detect lower GI cancers,
including colorectal (colon, rectum, caecum) or
anal cancers, in adult populations (mean/me-
dian age 18 or older; studies including individ-
uals aged less than 18 were accepted if these
were outliers in large samples). Non-specified GI
cancers, neuroendocrine cancers, and studies
only reporting on familial populations at risk of
hereditary cancers were excluded.
Novel biomarkers were considered individu-
ally, in combination or as part of a panel. Studies
reporting only on a single, established biomarker
(CEA, CA19-9, or FIT or FOBT) were excluded
[16, 17]. Studies providing measures of diagnos-
tic performance for combinations of established
and novel biomarkers were included.
Covidence systematic review software [18]
was used to facilitate article screening. Titles and
abstracts were screened independently by two
reviewers (any two of PD, NC, CS, KM, DB or RB).
Full-text articles were also independently evalu-
ated for inclusion by two reviewers (any two of
the aforementioned). Reference lists of included
studies weremanually reviewed by one author to
identify additional studies (NC). Full-text articles
selected at this stage were also independently
assessed by two reviewers (any two of PD, NC, RB
or DB). Disagreements were resolved by consen-
sus; when this could not be reached, a senior
reviewer was consulted (JE or FMW).
Data Extraction and Analysis
Data extraction was piloted to ensure consis-
tency and was performed independently (by SS,
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DB, RB, JMG, JO). Information on study char-
acteristics, populations, biomarkers and mea-
sures of diagnostic performance were extracted.
When studies reported on different phases of
biomarker development, only data from the
eligible phases were extracted. When studies
had more than one eligible phase, data were
extracted for all eligible phases. Extracted data
were collated and checked for consistency and
inaccuracies (PD).
Biomarkers were categorised according to a
modified version of the classifications reported
by Uttley et al. [15]: microRNAs and other
RNAs, autoantibodies and other immunological
markers, other proteins (i.e. proteins that did
not fit into other categories), metabolic mark-
ers, DNA-related markers (protein-coding genes,
gene mutations), circulating tumour DNA, DNA
methylation markers and other biomarkers.
Controls were classified as normal/healthy,
having non-malignant conditions or those with
adenomas/polyps. Controls described as heal-
thy were coded as such unless studies described
underlying conditions. Full details of the con-
trol population classification are available in
Appendix 2 in the supplementary material.
Quality Assessment and Risk of Bias
Considering the key issue of spectrum bias,
studies were classified as either single-gate or
two-gate designs. Single-gate studies recruit
participants before disease status is known, with
a single route of entry, and with the same
inclusion criteria. Two-gate studies recruit par-
ticipants through different routes and use dif-
ferent criteria for cases and controls. This can
lead to over-inflated measures of diagnostic
performance for example if there is an over-
representation of individuals with advanced
disease within the study population and com-
parison with the ‘fittest of the fit’ healthy con-
trols [11]. One author (PD) classified all studies
and another (NC) checked the classification. A
full description of this classification and how it
approaches issues covered by the QUADAS-2
critical appraisal tool [19] is available in
Appendix 3 in the supplementary material.
Studies included in the meta-analysis were
assessed using the QUADAS-2 [19] tool by two
reviewers (PD and NC).
Data Synthesis
As significant heterogeneity was anticipated, we
used narrative synthesis to summarise the data
[20]. An overview of the evidence was devel-
oped to describe the key characteristics of the
included studies, their populations, biomarkers
and outcome measures. Data were examined for
similarities that would allow for subgroup
analyses, namely the same biomarker, with
similar study design and appropriate accuracy
performance measures. For meta-analysis to
occur, biomarkers had to be investigated in
more than two studies, with individual out-
come measures provided, similar populations
included and a single-gate study design. We
focused the analysis on single-gate studies, as
this design reduces spectrum bias, and is more
likely to provide results that translate for use in
low-prevalence populations. Meta-analysis of
diagnostic test accuracy was performed using
MetaDTA (version 1.43) [21] and RevMan (5.3)
[22] software.
For meta-analysis, we used the random
effects bivariate binomial model of Chu and
Cole fitted as a generalised linear mixed effect
model [21]. Sensitivity and specificity were
jointly modelled and the estimates from each
study were assumed to vary [21]. Hierarchical
summary receiver operating characteristic
(HSROC) parameters were estimated using the
bivariate model parameters. Summary points of
sensitivity and specificity were presented
alongside forest plots and SROC curves.
Heterogeneity and threshold effects were eval-
uated using the SROC plots and random effects
correlation.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
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RESULTS
A total of 16,597 records were identified in
database searches; 9172 were retained after
removing duplicates (Fig. 2). During title and
abstract screening 8179 records were excluded.
After assessing the full text of the remaining 993
records, 731 of them were excluded. Of the
remaining studies, 142 are included in this
review. The characteristics of included studies
are described further in Table 1, and measures of
diagnostic performance are described in sup-
plementary Table 1.
Characteristics of Included Studies
Most papers (n = 124) recruited patients from a
single country. China was the most common
country (n = 62), followed by Japan and Ger-
many (both n = 14), and the USA (n = 13). Most
studies recruited from single settings with few
studies recruiting from at least two different
settings (n = 11). The most common recruit-
ment settings were hospitals and other sec-
ondary care settings (n = 106). Only one study
recruited controls from a primary care setting
[57]. All included studies reported on CRC, with
six studies specifically referring to colon cancer,
and one study specifying rectal and caecum
cancer cases separately to colon cancer. Some
studies (n = 22) also referred to adenomas or
polyps as cases, and five studies also included
data on upper GI cancers (e.g. gastric, oeso-
phageal and pancreatic cancers).
Characteristics of Cases and Controls
Overall, the included studies reported on 24,844
cases; the majority were diagnosed with CRC
(80.2%) and a minority with adenomas/polyps
(19.8%). Most cases had their age reported
(79%), either as a range, mean or median. The
overall mean age for CRC cases was 61.3 years,
and 60.7 years for adenoma/polyp cases. The
minimum age for cases was 18 years, while the
oldest was 97 years old. The majority (59%) of
CRC and adenoma/polyp cases were male. Most
studies provided data on tumour staging,
mainly using the TNM system (n = 101), though
some studies used Dukes’ classification (n = 22),
with one study providing data for both. When
combining TNM and Dukes’ staging data, over
half of the cancers (54%) were diagnosed at
early stages (I–II/A ? B). Adenomas included as
cases were most frequently defined by size,
dysplasia, villous component and/or number of
adenomas.
The included studies reported on a total of
45,374 controls (31,352 normal/healthy, 6414
with non-malignant conditions and 7608 with
adenomas or polyps). A number of studies
(n = 37) investigated more than one type of
control population. The control populations of
most studies (n = 108) were tested to rule out
CRC, mainly using colonoscopy (n = 65). The
majority of studies (n = 17) with adenomas or
polyps as controls included those that were low
risk (hyperplastic, non-neoplastic polyps or
non-advanced adenomas), though some were
high risk (advanced adenomas, those with vil-
lous histology or high-grade dysplasia). Age data
were extractable for 47.1% of controls. The
minimum age for a control was 16 years (heal-
thy control), while the oldest was 99 years old.
The majority of both healthy (50.6%) and non-
malignant (58%) controls were male.
Types of Biomarkers
Most studies investigated more than one bio-
marker (79.6%), and these often reported on
measures of performance for individual and
combinations or panels of biomarkers (45.8%).
The commonest sample source was blood
(82.4%); these analysed serum (n = 62), plasma
(n = 41) or whole blood (n = 14). Faeces was also
a common sample source (24.6%); two studies
analysed urine, and 13 studies analysed more
than one type of sample.
A total of 378 unique biomarkers were
identified across the 142 included studies (Ap-
pendix 4 in the supplementary material). The
commonest biomarkers were microRNAs and
other RNAs, followed by proteins, DNAmarkers,
autoantibodies and other immunological
markers, and metabolic markers. Proteins were
further classified into subcategories, with the
most common being novel proteins (Table 2).
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Fig. 2 Study selection
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A total of 54 biomarkers were reported in
more than one study (Appendix 5 in the sup-
plementary material). Three biomarkers were
investigated by more than 10 studies: CA19-9,
CEA and mSEPT9 (methylated septin 9). Addi-
tionally, six other biomarkers were investigated
in five or more studies: tumour pyruvate kinase
isoenzyme type M2 (TuM2-PK), microRNA-21
(miR-21), FIT, microRNA-92a (miR-92a), cancer
antigen 72-4 (CA72-4) and TIMP metallopepti-
dase inhibitor 1 (TIMP-1) (see Appendix 5 for
references).
Measures of Diagnostic Performance
Individual measures of diagnostic performance
(i.e. measures outside of combinations or pan-
els) were available for 35 biomarkers evaluated
more than once (Appendix 5 in the supple-
mentary material). Heterogeneity of study
design and included populations precluded
meta-analysis for the majority of these
biomarkers; however, three had individual
measures from multiple studies adopting a
classic single-gate design: CEA (n = 7 studies),
mSEPT9 (n = 4 studies) and TuM2-PK (n = 3
studies). Differences in the sample sources and
diagnostic performance measures provided
across the studies precluded meta-analysis for
any accuracy measures available for CEA, which
was included as a comparator to the novel
markers. Meta-analysis was performed for the
markers mSEPT9 and TuM2-PK.
The estimated sensitivity and specificity of
mSEPT9 was 80.6% (95% CI 76.6–84.0%) and
88.0% (95% CI 79.1–93.4%), respectively, and
the diagnostic odds ratio was 30.3 (95% CI
17.8–51.4). TuM2-PK had an estimated sensi-
tivity of 81.6% (95% CI 75.2–86.6%) and a
specificity of 80.1% (95% CI 76.7–83.0%), and a
diagnostic odds ratio of 17.8 (95% CI
11.6–27.2). Paired forest plots of the sensitivity
and specificity for both mSEPT9 and TuM2-PK
are shown in Figs. 3 and 4.
The random effects correlation for mSEPT9
was - 1, indicating a significant threshold
effect. Heterogeneity and threshold effect were
harder to evaluate statistically for the meta-
analysis of TuM2-PK as the low number of
included studies impeded accurate fitting of the
HSROC curve and generation of a random
effects correlation. A cut-off value of 4 U/ml was
used for the TuM2-PK assays across all studies.
The studies included in the meta-analyses were
at low risk of bias across most domains, except
for the domains related to patient selection and
the index test. Full appraisal data can be found
in Appendix 6 in the supplementary material.
Summary plots including risk of bias and
applicability ratings from QUADAS-2 are shown
in Figs. 5 and 6.
DISCUSSION
This systematic review identified 142 studies
reporting on 378 different biomarkers for CRC.
The included papers were very heterogeneous,
Table 2 Classification of identified biomarkers
Identified biomarkers (142 studies) N (%)
MicroRNAs and other RNAs 126 (33.3%)




Adhesion and matrix proteins 11 (2.9%)
Classic tumour markers 6 (1.6%)
Coagulation and angiogenesis molecules 6 (1.6%)




Novel proteins 39 (10.3%)
Not otherwise specified 8 (2.1%)
Autoantibodies and other immunological
markers
44 (11.6%)
Metabolic markers 42 (11.1%)
Circulating tumour DNA 4 (1.1%)
DNA methylation 15 (4.0%)
Other biomarkersa 16 (4.2%)
a Other biomarkers included platelets, white blood cells,
red blood cells and colonocytes
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with differences in study design, control popu-
lations, sample sources, types of biomarkers,
test thresholds and reported performance mea-
sures. Meta-analysis of diagnostic accuracy data
was only possible for two novel markers:
mSEPT9 and TuM2-PK. Both demonstrated high
sensitivity, specificity and diagnostic odds ratios
in hospital populations.
The most common biomarkers (both indi-
vidually and in panels) were CEA, CA19-9,
mSEPT9 and TuM2-PK. CEA and CA19-9 have a
more established role in clinical practice for
detecting recurrent disease [3, 7] so it is not
surprising that these markers are prevalent
throughout the literature. Most of the studies
included CEA (42/53) and CA19-9 (20/21) in
panels or used them as comparators for novel
markers. Meta-analysis was not possible for
these studies because of heterogeneity in sam-
ple sources and performance measures. Twenty
studies reported on the performance of mSEPT9
for CRC detection, mostly as a blood-based
biomarker sampled from plasma. While most
measures of diagnostic performance were for
mSEPT9 as an individual marker, it was also
included in panels or combinations across seven
studies. Fewer studies reported on the perfor-
mance of TuM2-PK (nine overall, three included
TuM2-PK in panels or combinations). Unlike
mSEPT9, TuM2-PK was predominantly sampled
from stool, though some studies also reported it
as a blood-based biomarker. The studies that
evaluated mSEPT9 and TuM2-PK included a
number of two-gate studies or hybrid designs,
and multiple instances where the study design
was unclear. The meta-analyses for mSEPT9 and
TuM2-PK included only those with a clear,
classic single-gate design [11] to reduce hetero-
geneity and spectrum bias; consequently, both
meta-analyses included a low number of stud-
ies, resulting in wide confidence intervals for
the diagnostic odds ratios.
The meta-analysis for mSEPT9 synthesised
diagnostic performance data on 899 CRC cases.
Cancer cases were mostly diagnosed in stages II
or III and diagnostic performance data were also
provided for adenomas and polyps in most
cases. This is important to note, as the diag-
nostic performance results for early stage can-
cers are more likely to translate for use in early
detection, and the ability for biomarkers also to
detect high-risk adenomas, polyps or dysplasia
could provide additional clinical utility. Across
all studies, the test sensitivity was higher when
detecting advanced CRC cases. Conversely, test
sensitivity decreased when used to detect either
adenomas or degrees of dysplasia. As previously
mentioned, several studies evaluated mSEPT9
within diagnostic panels or in combination
with other markers. Three studies in particular
[66, 151, 153] showed the sensitivity of mSEPT9
to detect CRC increased when combined with
more established markers such as FIT and CEA.
The results from our review show a slightly
higher sensitivity for mSEPT9 in comparison to
a recent meta-analysis of 19 studies [165]
Fig. 3 Forest plots of sensitivity and specificity for mSEPT9 in plasma
Fig. 4 Forest plots of sensitivity and specificity for TuM2-PK in stool
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though it should be noted the analysis from
that review included a mixture of study designs
and focused on high-risk populations. Our
results are comparable to previous analyses
which estimated the sensitivity of mSEPT9 as up
to 88% [165, 166].
The meta-analysis of diagnostic accuracy
data for TuM2-PK as a stool marker included
183 CRC cases. Similarly to mSEPT9, the sensi-
tivity of TuM2-PK was higher for more
advanced cancers (Dukes’ stage C and D; stages
III and IV) and lower when it was used to detect
adenomas, polyps or dysplasia. All three studies
included in the meta-analysis compared the
diagnostic performance of TuM2-PK to the
established stool marker FIT, and demonstrated
that FIT was preferable to TuM2-PK as a faecal
biomarker for screening populations
[94, 116, 117]. Three studies [50, 67, 115] eval-
uated TuM2-PK as a blood-based biomarker in
combination with other markers or in panels,
and all found sensitivity to be higher for TuM2-
PK in combination with other markers. TuM2-
PK may therefore be more promising in blood-
based diagnostic panels than as a stand-alone
stool marker.
Two-gate and hybrid designs were used
widely in the included studies. These types of
study designs can lead to over-inflated measures
of diagnostic performance due to an over-
Fig. 5 HSROC curve for mSEPT9 (with risk of bias and applicability ratings)
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representation of individuals with advanced
disease within the study population [11]. While
many studies attempted single-gate designs and
recruited participants through one route (usu-
ally screening populations where all partici-
pants attended for a colonoscopy), the low
prevalence of CRC cases meant that extra cases
were sourced from alternative routes. This study
design issue highlights the importance of large-
scale studies and trials that are adequately
powered to evaluate diagnostic performance in
truly low-prevalence populations.
Several other methodological limitations
were identified across the studies. These inclu-
ded the parallel analysis of large numbers of
biomarkers during discovery studies; limited
external, independent validation of test perfor-
mance; and selective reporting for validation
including alternative analyses and combina-
tions or use of several cut-off points. Insufficient
reporting regarding population characteristics
and recruitment was also an issue in many
studies, with information often provided as
supplementary data and with little detail. As a
result of the large amount of evidence on bio-
marker development and evaluation, we believe
the field could benefit from a ‘‘living systematic
review’’; this refers to high-quality, up-to-date
online summaries of evidence which can be
constantly updated as new research becomes
available [167].
Fig. 6 HSROC plot for TuM2-PK (with risk of bias and applicability ratings)
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Although our search was restricted to studies
published in English, recent reviews indicate
that this has minimal impact on review con-
clusions [168, 169]. Further limitations of this
review include the exclusion of studies that
evaluated biomarkers within risk assessment
tools or risk prediction models. These studies
have strong potential to be used in the com-
munity; however, we believe they should be
investigated in a separate systematic review.
The heterogeneity of the published literature
meant we could only conduct meta-analyses on
a limited subset of included studies. Nonethe-
less, we believe the narrative synthesis of addi-
tional studies provides a useful summary of the
current state of the science in this area. There
was insufficient homogeneous data on bio-
marker panels to report summary estimates of
their diagnostic performance. A study from
Fung et al. [48] describes ColoSTAT, a novel
blood-based diagnostic panel for CRC that
includes TuM2-PK with two other biomarkers
(IL-8 and DKK-3) and is currently being trialled
in Australia. The ColoSTAT panel has reported
sensitivity and specificity of 73% and 95%,
respectively, for CRC, which is comparable to
reported values for FIT (64–73% and 92–95%,
respectively [170–173]) for the detection of CRC
in screening populations. Previous trials using
this panel have been conducted in high-preva-
lence settings, with two-gate designs. Once
further data are available on ColoSTAT and its
performance to detect early stage CRC, it may
have applicability in low-prevalence settings as
an alternative to FIT, either for screening or in
symptomatic populations.
CONCLUSION
There is a large body of evidence on novel
biomarkers being developed to aid with the
early detection of lower GI cancers. Few of these
markers have yet demonstrated their validity or
clinical utility, but two show promise for further
evaluation, mSEPT9 and TuM2-PK, and could
contribute towards the early detection of CRC
as part of blood-based diagnostic panels. Fur-
ther, large-scale studies in low-prevalence pop-
ulations are required to evaluate their potential
role to support diagnostic assessment in pri-
mary care and community settings. This review
offers a comprehensive overview of the current
state of evidence, situates it within a transla-
tional framework for diagnostic tests and makes
recommendations in order to build the evi-
dence base for the early detection of lower GI
cancers in low-prevalence settings.
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